Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Clinical data suggest that treatment with OM-85, by inducing an early contact with bacterial
extracts, could modulate the immunity of children with Atopic Dermatitis, and thus play an
active role in the treatment of Atopic Dermatitis.
The present trial will investigate the influence of administration of OM-85 in the paediatric
population younger than 24 months with moderate atopic dermatitis.
The efficacy and safety of OM-85 will be evaluated in children aged 3 to 24 months old with
moderate Atopic Dermatitis who may benefit from treatment with OM-85. The placebo treatment
period will serve as a reference and has been added to establish efficacy and safety.